• Kerkhofs TM, Ettaieb MH, Hermsen IG, Haak HR.
    Developing treatment for adrenocortical carcinoma.
    Endocr Relat Cancer. 2015 Dec;22(6)
  • Kerkhofs TM, Roumen RM, Demeyere TB, van der Linden AN, Haak HR.
    Adrenal tumors with unexpected outcome: a review of the literature.
    Int J Endocrinol. 2015;2015:710514.
  • Kerkhofs TM, Kerstens MN, Kema IP, Willems TP, Haak HR.
    Diagnostic Value of Urinary Steroid Profiling in the Evaluation of Adrenal Tumors.
    Horm Cancer. 2015 Aug;6(4):168-75
  • Berruti et al. Adrenal Cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.
    Ann Oncol. 2012 Oct;23 Suppl 7:vii131-8
  • Arlt W et al. Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors.
    JCEM 2011 Dec;96(12):3775-84
  • Fassnacht M et al. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?
    Clin Endocrinol (Oxf). 2010 Nov;73(5):561-5
  • Hermsen IG, Polak MP, Haak HR. Disappearing adrenal masses.Endocrine. 2010 Oct;38(2):153-7.
  • Fassnacht M, Allolio B. Clinical Management of adrenocortical carcinoma
    Best Pract Res Clin Endocrinol Metab. 2009 Apr;23(2):273-89
  • van Ditzhuijsen CI, van de Weijer R, Haak HR. Adrenocortical carcinoma.
    Neth J Med. 2007 Feb;65(2):55-60.